Bjornson C, et al. - Researchers evaluated the effectiveness and adverse events related to palivizumab (PVZ) for prophylaxis for respiratory syncytial virus in cystic fibrosis (CF) infants. The Canadian registry of palivizumab (CARESS) vs untreated (UPVZ) infants from Alberta indicated similar odds of RSV hospitalizations (RSVH) between groups, however, PVZ subjects showed decreased odds of respiratory-related illness (RIH). The number of RSV tests performed was low explaining the similarity in RSVH rates. Significant differences in length of overall stay (LOS) might suggest decreased RSVH and RIH illness severity in the PVZ group compared to UPVZ group.